

Yaron Rotman, MD, MSc

Curriculum Vitae

March 11, 2011

Academic Positions

- 8/2009–present Assistant Clinical Investigator, Liver Diseases Branch, NIDDK, NIH, Bethesda, MD
- 2003 -2006 Instructor, Dept. of Internal Medicine, Sackler Medical School, Tel-Aviv University, Israel

Clinical Training & Experience

- 7/2006–8/2009 Clinical Liver Fellow, Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA
- 1/2004–6/2006 Fellow, Gastroenterology & Liver Institutes, Rabin Medical Center, Beilinson Campus, Israel. Chief fellow from 4/2005.
- 6/2000-12/2003 Resident, Dept. of Medicine D, Rabin Medical Center, Beilinson Campus, Israel
- 4/2000-5/2000 On-call physician, Dept. of Medicine D, Rabin Medical Center, Beilinson Campus, Israel
- 4/1999-3/2000 Rotating Internship, Assaf Harofeh Hospital

Education

- 2000 M.D., Hadassah Medical School, Hebrew University, Jerusalem
- 2000 M.Sc. (summa cum laude) in Neurobiology, Faculty of Medicine, Hebrew University. Studying under Dr. Israel Nelken.
- 1995 B.Sc.Med. (cum laude), Hadassah Medical School

Publications

- Nelken, I., Rotman, Y., and Bar Yosef, O. **1997**. Specializations of the auditory system for the analysis of natural sounds. In: *Central Auditory Processing and Neural Modeling*, Brugge, J. F., and Poon, P. F. (eds), 43-54: Plenum Press.
- Rotman, Y. **1999**. Relating the Responses to Natural Sounds and Tonal Stimuli in the Primary Auditory Cortex of Cats. **M.Sc. Thesis**. Hebrew University, Jerusalem (Hebrew).
- Nelken, I., Rotman, Y., and Bar Yosef, O. **1999**. Responses of auditory-cortex neurons to structural features of natural sounds. **Nature** 397 (6715), 154-157.
- Rotman, Y., Bar-Yosef, O., and Nelken, I. **2001**. Relating cluster and population responses to natural sounds and tonal stimuli in cat primary auditory cortex. **Hear Res** 152 (1-2), 110-127.
- Rotman, Y., and Tur-Kaspa, R. **2001**. Transmission of hepatitis B and C viruses--update. **Isr Med Assoc J** 3 (5), 357-359.
- Bar-Yosef, O., Rotman, Y., and Nelken, I. **2002**. Responses of neurons in cat primary auditory cortex to bird chirps: effects of temporal and spectral context. **J Neurosci** 22 (19), 8619-8632.
- Schmilovitz-Weiss, H., Tovar, A., Halpern, M., Sulkes, J., Braun, M., Rotman, Y., Tur-Kaspa, R., and Ben-Ari, Z. **2006**. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection. **J Viral Hepat** 13 (10), 671-677.
- Cohen, M., Bachmatov, L., Ben-Ari, Z., Rotman, Y., Tur-Kaspa, R., and Zemel, R. **2007**. Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection. **Dig Dis Sci** 52 (9), 2427-2432.

- Schmilovitz-Weiss, H., Niv, Y., Pappo, O., Halpern, M., Sulkes, J., Braun, M., Barak, N., Rotman, Y., Cohen, M., Waked, A., Tur-Kaspa, R., and Ben-Ari, Z. **2008**. The 13C-Caffeine Breath Test Detects Significant Fibrosis in Patients With Nonalcoholic Steatohepatitis. *J Clin Gastroenterol* 42 (4), 408-412.
- von Rosenvinge, E. C., Koh, C., Rotman, Y., and Lim, R. M. **2008**. Electronic clinical challenges and images in GI. Gastrointestinal malignant melanoma. *Gastroenterology* 135 (1), e5-6.
- Rotman, Y., and Liang, T. J. **2009**. Hepatitis C Virus. In: *Clinical Virology*, Richman, D. D., Whitley, R. J., and Hayden, F. G. (eds). Washington, DC: ASM Press.
- Rotman, Y., Katz, L., Cohen, M., Cohen-Ezra, O., Manhaim, V., Braun, M., Ben-Ari, Z., and Tur-Kaspa, R. **2009**. Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C. *J Viral Hepat* 16 (5), 340-345.
- Rotman, Y., Brown, T. A., and Hoofnagle, J. H. **2009**. Evaluation of the patient with hepatitis B. *Hepatology* 49 (S5), S22-S27.
- Rotman, Y., and Liang, T. J. **2009**. Coinfection of Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes. *J Virology* 83 (15), 7366-7374.
- Ahlenstiel, G., Titerence, R. H., Koh, C., Edlich, B., Feld, J. J., Rotman, Y., Ghany, M. G., Hoofnagle, J. H., Liang, T. J., Heller, T. and Rehermann, B. **2010**. Natural Killer Cells are Polarized towards Cytotoxicity in Chronic Hepatitis C in an Interferon-alpha-Dependent Manner. *Gastroenterology* 138 (1), 325-335.
- Feld, J. J., Lutchman, G. A., Heller, T., Hara, K., Pfeiffer, J. K., Leff, R. D., et al. **2010**. Ribavirin improves early responses to peginterferon through improved interferon signaling. *Gastroenterology*, 139(1), 154-162 e154.

- Feld, J. J., Modi, A. A., El-Diwany, R., Rotman, Y., Thomas, E., Ahlenstiel, G., et al. **2010**. S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. *Gastroenterology*.
- Rotman, Y., Borg, B. B., Soza, A., Feld, J. J., Modi, A. A., Loomba, R., et al. **2010**. Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. *Aliment Pharmacol Ther*, 31(9), 1018-1027.
- Rotman, Y., Koh, C., Zmuda, J. M., Kleiner, D. E., & Liang, T. J. **2010**. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. *Hepatology*, 52(3), 894-903.

Abstracts & Presentations

- Zemel, R., Rotman, Y., Y., B., Bachmatove, L., Kunin, M., Golan-Goldhirsh, A., Tur-Kaspa, R., and Benhar, I. A High Throughput Assay for Identification of Hepatitis C Virus NS3 Serine Protease Inhibitors. **8th International Symposium on Hepatitis C Virus & Related Viruses**, Paris, France, 2001.
- Zemel, R., Rotman, Y., Y., B., Bachmatove, L., Kunin, M., Golan-Goldhirsh, A., Tur-Kaspa, R., and Benhar, I. A High Throughput Assay for Identification of Hepatitis C Virus NS3 Serine Protease Inhibitors. **AASLD Liver Meeting**, Dallas, 2001.
- Nahary, L., Zemel, R., Rotman, Y., Bachmatove, L., Benhar, I., and Tur-Kaspa, R. Inhibition of the cell-proliferative potential of the hepatitis C virus core protein by recombinant intracellular antibodies. **AASLD Liver Meeting**, Boston, 2002.

- Zemel, R., Bachmatove, L., Drori, R., Rotman, Y., Tur-Kaspa, R., and Barak, N. Augmentation of PPAR-alpha expression induced by hepatitis C virus core protein. **Israeli Association for the Study of the Liver Annual Meeting**, Haifa, Israel, 2003.
- Zemel, R., Barak, N., Bachmatove, L., Drori, R., Rotman, Y., and Tur-Kaspa, R. Augmentation of PPAR-alpha expression induced by hepatitis C virus core protein. **AASLD Liver Meeting**, Boston, 2003.
- Braun, M., Pappo, O., Zuckerman, E., Sulkes, J., Kitai, Y., Moreno, M., Cohen, O., Weiss, H. S., Rotman, Y., Zamir, D., Melnik, S., Kaspa, R. T., and Ben Ari, Z. The unique breathid test system diagnoses and predicts the extent of hepatic injury in patients with nonalcoholic fatty liver disease. **AASLD Liver Meeting**, San Francisco, 2005.
- Cohen, M., Zemel, R., Bachmatov, L., Benari, Z., Rotman, Y., and Turkaspa, R. Novel F protein in chronic hepatitis C virus infection. **AASLD Liver Meeting**, San Francisco, 2005.
- Rotman, Y., Ben-Ari, Z., Braun, M., Cohen, M., Cohen-Ezra, O., Manhaim, V., and Tur-Kaspa, R. Low body weight predicts PEG-interferon alfa-2a (PEGASYS) induced neutropenia in chronic hepatitis C patients. **AASLD Liver Meeting**, San Francisco, 2005.
- Braun, M., Pappo, O., Margalit, M., Lazar, G., Zuckerman, E., Kitai, Y., Barak, N., Dan, A., Cohen, O., Weiss, H. S., Rotman, Y., Zamir, D., Melnik, S., Tur-Kaspa, R., and Ben-Ari, Z. Detection of nonalcoholic steatohepatitis and the extent of hepatic fibrosis with the innovative real-time BreathID (R) test system in patients with NAFLD. **AASLD Liver Meeting**, Boston, 2006.
- Braun, M., Pappo, O., Zuckerman, E., Sulkes, J., Kitai, Y., Cohen, O., Weiss, H. S., Rotman, Y., Zamir, D., Melnik, S., Tur-Kaspa, R., and Ari, Z. B. The innovative continuous BreathID (R) test system predicts the extent of hepatic injury in patients with nonalcoholic fatty liver disease. **Digestive Diseases Week**, Los Angeles, 2006.

- Braun, M., Pappo, O., Zuckerman, E., Sulkes, J., Kitai, Y., Moreno, M., Cohen, O., Shmilovitz-Weiss, H., Rotman, Y., Zamir, D., Melnik, S., Tur-Kaspa, R., and Ben-Ari, Z. The innovative real time Breath-ID (R) test system diagnoses and predicts the extent of hepatic injury in patients with non-alcoholic fatty liver disease. **EASL Annual Meeting**, Vienna, Austria, 2006.
- Rotman, Y., Ben-Ari, Z., Braun, M., Cohen, M., Cohen-Ezra, O., Manhaim, V., and Tur-Kaspa, R. Low body weight predicts PEG-interferon alfa-2a (PEGASYS) induced neutropenia in chronic hepatitis C patients. **Israeli Association for the Study of the Liver Annual Meeting**, Eilat, Israel, 2006.
- Rotman, Y., Ben-Bassat, O., Waked, A., and Niv, Y. The Oridion BreathID system for determining gastric emptying rate yields superior results to previously described breath-test protocol. **Israeli Gastroenterology Association Meeting**, Herzeliya, Israel, 2006.
- Rotman, Y., Levi, Z., Hazazi, R., Cohen, M., Cohen-Ezra, O., Braun, M., Ben-Ari, Z., and Tur-Kaspa, R. Serum lipoprotein levels during treatment of chronic hepatitis C with PEG-interferon-alpha-2a & ribavirin - A differential effect on genotype 3 patients. **Israeli Association for the Study of the Liver Annual Meeting**, Eilat, Israel, 2006.
- Rotman, Y., Levi, Z., Hazazi, R., Cohen, M., Cohen-Ezra, O., Manhaim, V., Braun, M., Ben-Ari, Z., and Tur-Kaspa, R. Serum lipoprotein levels during treatment of chronic hepatitis C with PEG-interferon-alpha-2a & ribavirin - A differential effect on genotype 3 patients. **EASL Annual Meeting**, Vienna, Austria, 2006.
- Rotman, Y., Levi, Z., Rachel, H., Cohen, M., Cohen-Ezra, O., Marhaim, V., Braun, M., Ben-Ari, Z., and Tur-Kaspa, R. Serum lipoprotein levels during treatment of chronic hepatitis C with PEG-interferon-alfa-2a & ribavirin - a differential effect on genotype 3 patients. **Digestive Diseases Week**, Los Angeles, 2006.

- Feld, J. J., Lutchman, G. A., Loomba, R., Modi, A. A., Rotman, Y., Nagabhyru, P. R., Ghany, M., Heller, T., Haynes-Williams, V., Liang, T. J., Neumann, A. U., and Hoofnagle, J. H. Twice vs once weekly dosing of peginterferon alfa 2A in chronic HCV genotype 1 infection: Analysis of early viral kinetics. **AASLD Liver Meeting**, Boston, 2007.
- Rotman, Y., Borg, B. B., Soza, A., Loomba, R., Modi, A. A., Feld, J. J., Rivera, E., Doo, E., Heller, T., Ghany, M., Neumann, A. U., Liang, T. J., and Hoofnagle, J. H. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis C, genotype 2 & 3: Viral kinetics, efficacy and safety. **AASLD Liver Meeting**, Boston, 2007.
- Ahlenstiel, G., Titerence, R. H., Koh, C., Feld, J. J., Rotman, Y., Ghany, M. G., Kleiner, D. E., Hoofnagle, J. H., Liang, T. J., Heller, T., and Rehermann, B. Disease Activity in Chronic Hepatitis C Correlates to Ifn-Alpha-Dependent Polarization of Natural Killer Cell Function Towards Cytotoxicity. **AASLD Liver Meeting**, San Francisco, 2008.
- Feld, J. J., Ko, M. S., Hara, K., Lutchman, G. A., Rotman, Y., Heller, T., Ghany, M. G., Neumann, A. U., Liang, T. J., and Hoofnagle, J. H. Ribavirin Improves Second Phase Kinetics through Enhanced Interferon Signaling in Genotype 1 Hcv Infection. **AASLD Liver Meeting**, San Francisco, 2008.
- Feld, J. J., Modi, A. A., Ahlenstiel, G., El-Diwany, R., Rotman, Y., Koh, C., Titerence, R., Park, Y., Ghany, M., Heller, T., Hoofnagle, J. H., and Liang, T. J. SAMe Improves Early Viral Kinetics and Interferon Stimulated Gene Induction When Added to Peginterferon and Ribavirin Therapy for Previous Hepatitis C Non-Responders. **AASLD Liver Meeting**, San Francisco, 2008.
- Rotman, Y., Koh, C., Feld, J. J., Kleiner, D. E., Liang, T. J., and Hoofnagle, J. H. Correlation of Biochemical and Histological Responses in Therapeutic Trials of Nonalcoholic Steatohepatitis (NASH). **AASLD Liver Meeting**, San Francisco, 2008.

- Feld, J. J., Modi, A. A., El-Diwany, R., Ahlenstiel, G., Rotman, Y., Koh, C., Titerence, R., Park, Y., Ghany, M., Heller, T., Hoofnagle, J. H., and Liang, T. J. SAMe Improves Early Viral Kinetics and Interferon Stimulated Gene Induction When Added to Peginterferon and Ribavirin Therapy for Previous Hepatitis C Non-Responders. **13th International Symposium on Viral Hepatitis and Liver Disease**, Washington, DC, 2009.
- Ghany, M. G., Feld, J. J., Heller, T., Doo, E. C., Rotman, Y., Nagabhyru, R., Koh, C., Kleiner, D. E., Liang, T. J., and Hoofnagle, J. H. Comparison of Long-Term Combination Therapy Using Adefovir and Lamivudine to Monotherapy Using Adefovir Alone for Chronic Hepatitis B. **13th International Symposium on Viral Hepatitis and Liver Disease**, Washington, DC, 2009.
- Heller, T., Rotman, Y., Haynes-Williams, V., Ghany, M. G., Liang, T. J., and Hoofnagle, J. H. Long-Term, High-Dose Peginterferon Alfa-2a for Chronic Hepatitis D: Safety and Efficacy. **13th International Symposium on Viral Hepatitis and Liver Disease**, Washington, DC, 2009.
- Heller T, Rotman Y, Haynes-Williams V, Kleiner DE, Ghany MG, Liang TJ, et al. Long-Term, High-Dose Peginterferon Alfa-2a Is an Effective Treatment for Chronic Hepatitis D. **AASLD Liver Meeting**, Boston 2009.
- Noureddin M*, Rotman Y*, Feld J, Koh C, Abdalla A, Thomas E, et al. The Effects of Ribavirin on Serum Hcv Levels before and during Combination Treatment with Peginterferon. **AASLD Liver Meeting**, Boston 2009.
- Thomas, E., Gonzalez, V. D., Modi, A. A., Noureddin, M., Rotman, Y., & Liang, T. J. Characterization of the interferon lambda (IL28/29) antiviral pathway in cell culture, human and chimpanzee models of HCV infection. **8th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research**, Chicago, IL 2010